COST-EFFECTIVENESS OF RIVAROXABAN WITHIN SUBGROUPS FOR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM IN THE NETHERLANDS

被引：0
|
作者：
Gout-Zwart, J. [1 ]
Sediq, A. [1 ]
van den Bosch, M. [2 ]
Postma, M. J. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Bayer BV, Mijdrecht, Netherlands
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1758
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV90
引用
收藏
页码：A652 / A652
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
    Wei, Hongtao
    Cui, Can
    Cui, Xiangli
    Liu, Yi
    Li, Dandan
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [32] Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
    Joris Kleintjens
    Xiao Li
    Steven Simoens
    Vincent Thijs
    Marnix Goethals
    Ernst R. Rietzschel
    Yumi Asukai
    Ömer Saka
    Thomas Evers
    Petra Faes
    Stefaan Vansieleghem
    Mimi De Ruyck
    PharmacoEconomics, 2013, 31 : 909 - 918
  • [33] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
  • [34] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [35] Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK
    Folkerts, Kerstin
    Broughton, Julie
    Sheikh, Usman
    Mckaig, Sasha
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) : 1179 - 1191
  • [36] Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
    Lefebvre, Patrick
    Coleman, Craig I.
    Bookhart, Brahim
    Wang, Si-Tien
    Mody, Samir H.
    Tran, Kevin
    Zhuo, Daisy
    Huynh, Lynn
    Nutescu, Edith A.
    PHARMACOTHERAPY, 2013, 33 (10): : E227 - E227
  • [37] Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
    Kleintjens, Joris
    Li, Xiao
    Simoens, Steven
    Thijs, Vincent
    Goethals, Marnix
    Rietzschel, Ernst R.
    Asukai, Yumi
    Saka, Omer
    Evers, Thomas
    Faes, Petra
    Vansieleghem, Stefaan
    De Ruyck, Mimi
    PHARMACOECONOMICS, 2013, 31 (10) : 909 - 918
  • [38] COST-EFFECTIVENESS OF RIVAROXABAN IN THE PREVENTION OF STROKE IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN ITALY
    Capri, S.
    Veneziano, M.
    Ricciardi, W. G.
    D'Ausilio, A.
    Pedone, M. P.
    Bianchi, C.
    VALUE IN HEALTH, 2013, 16 (07) : A525 - A526
  • [39] Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism
    Howe, Zachary
    Naville-Cook, Chad
    Cole, Derek
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (02) : 280 - 286
  • [40] Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism
    Zachary Howe
    Chad Naville-Cook
    Derek Cole
    Journal of Thrombosis and Thrombolysis, 2019, 47 : 280 - 286
12345